IRIS Accounts Production v23.3.0.418 10607797 director 1.3.22 28.2.23 28.2.23 false true false false true false Ordinary 0.0200 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh106077972022-02-28106077972023-02-28106077972022-03-012023-02-28106077972021-02-28106077972021-03-012022-02-28106077972022-02-2810607797ns10:Originalns15:EnglandWales2022-03-012023-02-2810607797ns14:PoundSterlingns10:Original2022-03-012023-02-2810607797ns10:Originalns10:Director12022-03-012023-02-2810607797ns10:Original2022-03-012023-02-2810607797ns10:Original2023-02-2810607797ns10:Originalns10:PrivateLimitedCompanyLtd2022-03-012023-02-2810607797ns10:Originalns10:SmallEntities2022-03-012023-02-2810607797ns10:Originalns10:AuditExempt-NoAccountantsReport2022-03-012023-02-2810607797ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-03-012023-02-2810607797ns10:SmallCompaniesRegimeForAccountsns10:Original2022-03-012023-02-2810607797ns10:Originalns10:FullAccounts2022-03-012023-02-2810607797ns10:Originalns10:OrdinaryShareClass12022-03-012023-02-2810607797ns10:Originalns10:RegisteredOffice2022-03-012023-02-2810607797ns10:Original2022-02-2810607797ns10:Originalns5:CurrentFinancialInstruments2023-02-2810607797ns10:Originalns5:CurrentFinancialInstruments2022-02-2810607797ns10:Originalns5:Non-currentFinancialInstruments2023-02-2810607797ns10:Originalns5:Non-currentFinancialInstruments2022-02-2810607797ns5:ShareCapitalns10:Original2023-02-2810607797ns5:ShareCapitalns10:Original2022-02-2810607797ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-02-2810607797ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-02-2810607797ns10:Original2021-03-012022-02-2810607797ns10:Originalns5:PlantMachinery2022-02-2810607797ns10:Originalns5:PlantMachinery2022-03-012023-02-2810607797ns10:Originalns5:PlantMachinery2023-02-2810607797ns10:Originalns5:PlantMachinery2022-02-2810607797ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-02-2810607797ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-02-2810607797ns10:Originalns10:OrdinaryShareClass12023-02-2810607797ns10:Original1ns10:Director12022-02-2810607797ns10:Original1ns10:Director12021-02-2810607797ns10:Original1ns10:Director12022-03-012023-02-2810607797ns10:Original1ns10:Director12021-03-012022-02-2810607797ns10:Original1ns10:Director12023-02-2810607797ns10:Original1ns10:Director12022-02-28
REGISTERED NUMBER: 10607797 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2023

FOR

MESOPOTAMIA MEDICALS LIMITED

MESOPOTAMIA MEDICALS LIMITED (REGISTERED NUMBER: 10607797)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


MESOPOTAMIA MEDICALS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 28 FEBRUARY 2023







DIRECTOR: Dr M El-Deen





REGISTERED OFFICE: 5 Manor Close
Kilmsersdon
Radstock
Somerset
BA3 5GE





REGISTERED NUMBER: 10607797 (England and Wales)





ACCOUNTANTS: Kimberlee & Co
Chartered Accountants
Hunt House Farm
Frith Common
Tenbury Wells
Worcestershire
WR15 8JY

MESOPOTAMIA MEDICALS LIMITED (REGISTERED NUMBER: 10607797)

BALANCE SHEET
28 FEBRUARY 2023

28.2.23 28.2.22
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 47,544 1,080

CURRENT ASSETS
Debtors 5 66,462 51,565
Cash at bank 53,060 21,023
119,522 72,588
CREDITORS
Amounts falling due within one year 6 16,464 15,364
NET CURRENT ASSETS 103,058 57,224
TOTAL ASSETS LESS CURRENT
LIABILITIES

150,602

58,304

CREDITORS
Amounts falling due after more than one
year

7

41,752

-
NET ASSETS 108,850 58,304

CAPITAL AND RESERVES
Called up share capital 8 1 1
Retained earnings 108,849 58,303
SHAREHOLDERS' FUNDS 108,850 58,304

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 28 February 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 28 February 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

MESOPOTAMIA MEDICALS LIMITED (REGISTERED NUMBER: 10607797)

BALANCE SHEET - continued
28 FEBRUARY 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 24 November 2023 and were signed by:





Dr M El-Deen - Director


MESOPOTAMIA MEDICALS LIMITED (REGISTERED NUMBER: 10607797)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2023

1. STATUTORY INFORMATION

Mesopotamia Medicals Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2022 - 1 ) .

MESOPOTAMIA MEDICALS LIMITED (REGISTERED NUMBER: 10607797)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2023

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 March 2022 2,094
Additions 62,666
At 28 February 2023 64,760
DEPRECIATION
At 1 March 2022 1,014
Charge for year 16,202
At 28 February 2023 17,216
NET BOOK VALUE
At 28 February 2023 47,544
At 28 February 2022 1,080

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
28.2.23 28.2.22
£    £   
Trade debtors 3,051 3,549
Other debtors 63,411 48,016
66,462 51,565

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
28.2.23 28.2.22
£    £   
Hire purchase contracts 13,942 -
Taxation and social security 1,344 14,229
Other creditors 1,178 1,135
16,464 15,364

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
28.2.23 28.2.22
£    £   
Hire purchase contracts 41,752 -

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 28.2.23 28.2.22
value: £    £   
500 Ordinary £.002 1 1

MESOPOTAMIA MEDICALS LIMITED (REGISTERED NUMBER: 10607797)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 28 FEBRUARY 2023

9. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 28 February 2023 and 28 February 2022:

28.2.23 28.2.22
£    £   
Dr M El-Deen
Balance outstanding at start of year 47,448 3,199
Amounts advanced 15,438 44,249
Amounts repaid - -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 62,886 47,448